Advertisement

Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients

  • Rurina Watanuki
  • Tetsu HayashidaEmail author
  • Yuko Kawai
  • Masayuki Kikuchi
  • Ayako Nakashoji
  • Takamichi Yokoe
  • Tomoka Toyota
  • Tomoko Seki
  • Maiko Takahashi
  • Yuko Kitagawa
Original Article
  • 66 Downloads

Abstract

Purpose

In adjuvant settings of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, anthracycline-based chemotherapy followed by taxane and trastuzumab is a standard regimen. Recent studies have reported the use of anthracycline-free adjuvant chemotherapy in selected HER2-positive breast cancer patients. We conducted a single-center retrospective study to identify the characteristics of HER2-positive breast cancer patients for whom anthracyclines can be safely omitted.

Methods

A total of 238 women were diagnosed with HER2-positive breast cancer and treated with neoadjuvant and/or adjuvant chemotherapy between January 1, 2008 and December 31, 2015 at Keio University Hospital. They were divided in two cohorts: an “anthracycline” cohort of 112 anthracycline-treated women and a “no anthracycline” cohort of 126 anthracycline-untreated women. Survival outcomes were estimated by Kaplan–Meier method.

Results

The 3-year disease-free survival rates in the no-anthracycline and anthracycline cohorts were 91.3% and 93.1%, respectively (P = 0.692). After using a statistical method with inverse probability of treatment weighting to minimize the selection bias, no significant differences were observed between the two cohorts (adjusted hazard ratio for disease-free survival: 1.042; P = 0.909). Stratified by tumor size, no significant differences were observed between the two cohorts in the cT1N0 and cT2N0 subsets (P = 0.516 and P = 0.579, respectively). The recurrence rate was low among patients who achieved pathological complete response after receiving neoadjuvant chemotherapy with or without anthracyclines.

Conclusion

Our study suggests that anthracyclines can be safely omitted in selected patients with HER2-positive breast cancer, who have cT1N0 or cT2N0 and achieved pathological complete response after receiving neoadjuvant chemotherapy.

Keywords

HER2-positive breast cancer Anthracycline Adjuvant chemotherapy Pathological complete response 

Abbreviations

CI

Confidence interval

DFS

Disease-free survival

HER2

Human epidermal growth factor receptor 2

IPTW

Inverse probability of treatment weighting

NCCN

National Comprehensive Cancer Network

OS

Overall survival

pCR

Pathological complete response

Notes

Acknowledgements

This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

T. Hayashida received research grants from Chugai, Kyowa Hakko Kirin and Shionogi and lecture fee from Chugai and Pfizer. Y. Kitagawa received research grants from Chugai, Kyowa Hakko Kirin and Shionogi, and lecture fee from Chugai. These are not directly unrelated to this study. All remaining authors have no conflicts of interest to declare.

References

  1. 1.
    Seshadri R, Firgaira FA, Horsfall DJ et al (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11(10):1936–1942CrossRefPubMedGoogle Scholar
  2. 2.
    Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182CrossRefPubMedGoogle Scholar
  3. 3.
    Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712CrossRefPubMedGoogle Scholar
  4. 4.
    Schramm A, De Gregorio N, Widschwendter P et al (2015) Targeted therapies in HER2-positive breast cancer—a systematic review. Breast Care (Basel) 10(3):173–178CrossRefGoogle Scholar
  5. 5.
    Wuerstlein R, Harbeck N (2017) Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials 12(2):81–92CrossRefPubMedGoogle Scholar
  6. 6.
    Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672CrossRefPubMedGoogle Scholar
  8. 8.
    Romond EH, Perez EA, Bryant J, et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684CrossRefPubMedGoogle Scholar
  9. 9.
    Yu AF, Mukku RB, Verma S, et al (2017) Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. Breast Cancer Res Treat 166(1):241–247CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Giordano SH, Lin YL, Kuo YF, et al (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30(18):2232–2239CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Burstein HJ, Piccart-Gebhart MJ, Perez EA et al (2012) Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol 30(18):2179–2182CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Morris PG, Hudis CA (2010) Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be? J Clin Oncol 28(21):3407–3410CrossRefPubMedGoogle Scholar
  13. 13.
    Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134–141CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Jones SE, Collea R, Paul D, et al (2013) Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol 14(11):1121–1128CrossRefPubMedGoogle Scholar
  15. 15.
    National Comprehensive Cancer Network website. http://www.nccn.org
  16. 16.
    Curtis LH, Hammill BG, Eisenstein EL et al (2007) Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care 45(10 Supl 2):S103–S107CrossRefPubMedGoogle Scholar
  17. 17.
    Cole SR, Hernan MA (2004) Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed 75(1):45–49CrossRefPubMedGoogle Scholar
  18. 18.
    Hernan MA, Robins JM (2006) Estimating causal effects from epidemiological data. J Epidemiol Community Health 60(7):578–586CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28(25):3083–3107CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48(3):452–458CrossRefPubMedGoogle Scholar
  21. 21.
    von Minckwitz G, Procter M, de Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122–131CrossRefGoogle Scholar
  22. 22.
    Gianni L, Pienkowski T, Im YH et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791–800CrossRefPubMedGoogle Scholar
  23. 23.
    Nakashoji A, Hayashida T, Yokoe T et al (2018) The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer. Cancer Treat Rev 62:9–17CrossRefPubMedGoogle Scholar
  24. 24.
    Nagayama A, Hayashida T, Jinno H et al. Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: a network meta-analysis. J Natl Cancer Inst. 2014;106(9)Google Scholar

Copyright information

© Japan Society of Clinical Oncology 2019

Authors and Affiliations

  • Rurina Watanuki
    • 1
  • Tetsu Hayashida
    • 1
    Email author
  • Yuko Kawai
    • 1
  • Masayuki Kikuchi
    • 1
  • Ayako Nakashoji
    • 1
  • Takamichi Yokoe
    • 1
  • Tomoka Toyota
    • 1
  • Tomoko Seki
    • 1
  • Maiko Takahashi
    • 1
  • Yuko Kitagawa
    • 1
  1. 1.Department of SurgeryKeio University School of MedicineTokyoJapan

Personalised recommendations